Migraine drug may boost CAR-T therapy in tough lymphoma

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to understand and voluntarily sign the written informed consent form. * Age 18 years or older. * Histologically confirmed large B-cell lymphoma with CD19 and CD20 expression. * Relapsed or refractory disease after at least one prior line of systemic therapy. * Prior treatment must have included an anthracycline-containing chemotherapy regimen and an anti-CD20 monoclonal antibody. * Considered suitable by the investigator to receive glofitamab and CD19 CAR-T cell therapy. * Presence of at least one high-risk feature, including extranodal involvement, bulky disease, or TP53 abnormality. * ECOG performance status of 0 to 2. * Life expectancy of at least 12 weeks. * Adequate bone marrow, hepatic, renal, pulmonary, and cardiac function as determined by the investigator. * Participants of reproductive potential must agree to use effective contraception during the study period. * Able and willing to comply with the study protocol, in the investigator's judgment. Exclusion Criteria: * History of hypersensitivity to any study treatment or related compounds. * Active or uncontrolled infection requiring systemic treatment. * History of allogeneic hematopoietic stem cell transplantation or organ transplantation. * Uncontrolled or clinically significant viral infection as defined by the protocol. * Known central nervous system involvement by lymphoma or clinically significant central nervous system disease that may interfere with study treatment or safety assessment. * Severe or uncontrolled cardiovascular disease. * Severe autoimmune disease or immune-mediated disease that may interfere with study treatment or safety assessment. * Known or suspected history of hemophagocytic lymphohistiocytosis. * Recent thromboembolic event before screening. * History of another malignancy within 5 years before screening, except adequately treated carcinoma in situ or non-melanoma skin cancer. * Receipt of prohibited anticancer therapy, immunosuppressive therapy, live attenuated vaccine, or other prohibited treatment within the protocol-specified period before enrollment. * Pregnant or breastfeeding women, or participants planning pregnancy during the study period. * Concurrent participation in another interventional clinical trial. * Need for prohibited concomitant medications that cannot be discontinued or substituted. * Any condition that, in the investigator's judgment, makes the participant unsuitable for study treatment or study participation.